Monobactam + beta-lactamase inhibitor
Aztreonam with avibactam
Brand names: Emblaveo
Adult dose
Dose: 2g/0.667g IV q6h (renal dose adjustment)
Route: IV
Frequency: q6h
Clinical pearls
- NICE TA evaluation: complicated intra-abdominal/UTI/HAP from MBL-producing Enterobacteriaceae
- Specialist microbiology — UKHSA AMR strategy
- Active where avibactam alone-cephalosporin combinations fail (MBL)
Contraindications
- Severe hypersensitivity to aztreonam
Side effects
- Hepatic enzyme elevation
- Diarrhoea
- Hypersensitivity
- C. difficile
Interactions
- Probenecid
Monitoring
- Renal
- C. diff
- LFTs
- Microbiology
Reference: BNF; NICE TA evaluation; UKHSA AMR; BSAC; SmPC; https://bnf.nice.org.uk/drugs/aztreonam-with-avibactam/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- C-Peptide to Glucose Ratio · Diabetes Classification
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023